Sign In
Buy BIIB
$207.94
+1.66 (+0.80%)
At Close: Aug 07, 2026
This analyst breaks down the bull case for Biogen's Alzheimer's drug
04:37am, Saturday, 19'th Nov 2022
CNBC's Kelly Evans and Bertha Coombs discuss Biogen's new Alzheimer's drug and the battle for medicare coverage with Michael Yee of Jefferies.
Cramer: There will be push back on Biogen's Alzheimer's drug price
04:08am, Saturday, 19'th Nov 2022
The Food and Drug Administration on Monday approved Biogen's Alzheimer's disease drug aducanumab, making it the first medication cleared by U.S. regulators to slow cognitive decline in people living w
Biogen upgraded to 'overweight' at Piper Sandler
03:51am, Saturday, 19'th Nov 2022
CNBC's Morgan Brennan takes a look at the Nasdaq Biotech ETF and its best performer Biogen.
FDA approves Biogen Alzheimer's treatment
02:21am, Saturday, 19'th Nov 2022
CNBC's Meg Tirrell reports on FDA approval of Biogen's Alzheimer's treatment under an 'accelerated approval pathway.'
FDA's historic approval of Biogen's Alzheimer's drug
02:12am, Saturday, 19'th Nov 2022
CNBC's Meg Tirrell on the FDA approval of Biogen's new Alzheimer's drug. With CNBC's Brian Sullivan and the Fast Money traders, Guy Adami, Tim Seymour and Karen Mills
Is Biogen (BIIB) a Great Value Stock Right Now?
11:17am, Thursday, 17'th Nov 2022
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
3 Stocks to Avoid Right Now
09:23am, Thursday, 17'th Nov 2022
Even though many stocks have fallen sharply in price, not all are bargains -- investors must remains selective.
Biotech Stocks Embrace The Neuroscience Renaissance With Biogen, Amylyx At The Helm
08:00am, Wednesday, 16'th Nov 2022
The neuroscience renaissance is here. Biotech stocks are soaring this year on expectations for new treatments in brain-health disorders.
One Alzheimer's drug has failed, but investors are still betting on Biogen and Lilly treatments
02:34pm, Monday, 14'th Nov 2022
Biogen's BIIB, +4.96% stock is rising again as investors double down on the company's promising yet still experimental treatment for Alzheimer's disease.
Biogen Stock Surges on Competitor's Downbeat Drug Data
10:57am, Monday, 14'th Nov 2022
While several sectors are taking a breather this morning, Biogen Inc (NASDAQ:BIIB) is climbing after major competitor Roche (ROG) said that its Alzheimer's drug candidate, gantenerumab, failed to meet
Why Is Biogen (BIIB) Stock Up Today?
10:16am, Monday, 14'th Nov 2022
Biogen (NASDAQ: BIIB ) stock is rising higher on Monday after Roche's (OTCMKTS: RHHBY ) Alzheimer's drug didn't perform well in a clinical trial. Roche has been developing a drug to treat Alzheimer's
What's Going On With Biogen Stock Today? - Biogen (NASDAQ:BIIB)
09:48am, Monday, 14'th Nov 2022
Biogen Inc (NASDAQ: BIIB) shares are trading higher Monday after competitor Roche's Alzheimer's candidate did not meet its primary endpoint in recent studies.
Roche's Alzheimer's Drug Fails In Phase 3; Here's The Fallout For Biogen, Lilly, Prothena And Others
09:17am, Monday, 14'th Nov 2022
Roche said its experimental Alzheimer's treatment failed in two final-phase studies, leading Biogen stock to surge while others crumbled. The post Roche's Alzheimer's Drug Fails In Phase 3; Here's The
Biogen shares jump 4.7% premarket on hopes for its Alzheimer's treatment lecanemab
06:41am, Monday, 14'th Nov 2022
Biogen Inc. shares BIIB, -0.43% rose 4.7% in premarket trade Monday, after MorphoSys and partner Roche said a trial of a treatment for Alzheimer's disease failed to meet its main goal. German-listed s
Biogen, Seagen Name New CEOs — But One Biotech Stock Crumbles
10:40am, Thursday, 10'th Nov 2022
Biogen and Seagen tapped new CEOs on Thursday but the biotech stocks diverged following the long-anticipated announcements. The post Biogen, Seagen Name New CEOs — But One Biotech Stock Crumbles app
